JP2019529495A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019529495A5 JP2019529495A5 JP2019517289A JP2019517289A JP2019529495A5 JP 2019529495 A5 JP2019529495 A5 JP 2019529495A5 JP 2019517289 A JP2019517289 A JP 2019517289A JP 2019517289 A JP2019517289 A JP 2019517289A JP 2019529495 A5 JP2019529495 A5 JP 2019529495A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- compound
- formula
- hydrogen
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 291
- 125000000217 alkyl group Chemical group 0.000 claims description 190
- 229910052739 hydrogen Inorganic materials 0.000 claims description 124
- 239000001257 hydrogen Substances 0.000 claims description 124
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 111
- 208000035475 disorder Diseases 0.000 claims description 96
- 150000003839 salts Chemical class 0.000 claims description 71
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 60
- 125000003342 alkenyl group Chemical group 0.000 claims description 50
- 125000000304 alkynyl group Chemical group 0.000 claims description 50
- 150000002431 hydrogen Chemical group 0.000 claims description 46
- 229910052799 carbon Inorganic materials 0.000 claims description 38
- 125000004432 carbon atom Chemical group C* 0.000 claims description 38
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 36
- 239000008194 pharmaceutical composition Substances 0.000 claims description 27
- 208000002193 Pain Diseases 0.000 claims description 24
- 125000003118 aryl group Chemical group 0.000 claims description 24
- 125000001072 heteroaryl group Chemical group 0.000 claims description 24
- 125000004043 oxo group Chemical group O=* 0.000 claims description 22
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 18
- 229930182558 Sterol Natural products 0.000 claims description 18
- 230000015572 biosynthetic process Effects 0.000 claims description 18
- 230000002496 gastric effect Effects 0.000 claims description 18
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 18
- 235000003702 sterols Nutrition 0.000 claims description 18
- 238000003786 synthesis reaction Methods 0.000 claims description 18
- 125000004452 carbocyclyl group Chemical group 0.000 claims description 16
- 125000001188 haloalkyl group Chemical group 0.000 claims description 16
- 208000014617 hemorrhoid Diseases 0.000 claims description 16
- 125000000623 heterocyclic group Chemical group 0.000 claims description 16
- 208000028017 Psychotic disease Diseases 0.000 claims description 15
- 201000010099 disease Diseases 0.000 claims description 15
- 230000002265 prevention Effects 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 13
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 12
- 208000011231 Crohn disease Diseases 0.000 claims description 12
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 12
- 210000003169 central nervous system Anatomy 0.000 claims description 12
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 12
- 201000000980 schizophrenia Diseases 0.000 claims description 12
- 150000003432 sterols Chemical class 0.000 claims description 12
- 208000000094 Chronic Pain Diseases 0.000 claims description 9
- 230000001154 acute effect Effects 0.000 claims description 9
- 208000005298 acute pain Diseases 0.000 claims description 9
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims description 8
- 125000001475 halogen functional group Chemical group 0.000 claims description 8
- 208000016583 Anus disease Diseases 0.000 claims description 7
- 208000024827 Alzheimer disease Diseases 0.000 claims description 6
- 206010002091 Anaesthesia Diseases 0.000 claims description 6
- 206010048946 Anal abscess Diseases 0.000 claims description 6
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 6
- 208000008958 Anti-N-Methyl-D-Aspartate Receptor Encephalitis Diseases 0.000 claims description 6
- 208000019901 Anxiety disease Diseases 0.000 claims description 6
- 208000023275 Autoimmune disease Diseases 0.000 claims description 6
- 208000020925 Bipolar disease Diseases 0.000 claims description 6
- 206010009944 Colon cancer Diseases 0.000 claims description 6
- 206010010144 Completed suicide Diseases 0.000 claims description 6
- 208000024581 Compulsive Personality disease Diseases 0.000 claims description 6
- 206010010774 Constipation Diseases 0.000 claims description 6
- 206010012289 Dementia Diseases 0.000 claims description 6
- 208000030814 Eating disease Diseases 0.000 claims description 6
- 206010072378 Encephalitis autoimmune Diseases 0.000 claims description 6
- 208000019454 Feeding and Eating disease Diseases 0.000 claims description 6
- 208000003456 Juvenile Arthritis Diseases 0.000 claims description 6
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims description 6
- 208000019022 Mood disease Diseases 0.000 claims description 6
- 208000016285 Movement disease Diseases 0.000 claims description 6
- 208000032580 NMDA receptor encephalitis Diseases 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- 208000029726 Neurodevelopmental disease Diseases 0.000 claims description 6
- 208000018737 Parkinson disease Diseases 0.000 claims description 6
- 201000009916 Postpartum depression Diseases 0.000 claims description 6
- 201000004681 Psoriasis Diseases 0.000 claims description 6
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 6
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 6
- 208000004680 Rectal Fistula Diseases 0.000 claims description 6
- 102100030681 SH3 and multiple ankyrin repeat domains protein 3 Human genes 0.000 claims description 6
- 101710101741 SH3 and multiple ankyrin repeat domains protein 3 Proteins 0.000 claims description 6
- 206010039897 Sedation Diseases 0.000 claims description 6
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims description 6
- 206010041247 Social fear Diseases 0.000 claims description 6
- 208000006011 Stroke Diseases 0.000 claims description 6
- 208000009205 Tinnitus Diseases 0.000 claims description 6
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 6
- 230000006978 adaptation Effects 0.000 claims description 6
- 230000037005 anaesthesia Effects 0.000 claims description 6
- 206010002156 anal fistula Diseases 0.000 claims description 6
- 208000029188 anti-NMDA receptor encephalitis Diseases 0.000 claims description 6
- 208000029560 autism spectrum disease Diseases 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 6
- 208000010877 cognitive disease Diseases 0.000 claims description 6
- 208000029742 colonic neoplasm Diseases 0.000 claims description 6
- 206010012601 diabetes mellitus Diseases 0.000 claims description 6
- 235000014632 disordered eating Nutrition 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 6
- 208000024732 dysthymic disease Diseases 0.000 claims description 6
- 206010015037 epilepsy Diseases 0.000 claims description 6
- 230000001037 epileptic effect Effects 0.000 claims description 6
- 230000001939 inductive effect Effects 0.000 claims description 6
- 206010022437 insomnia Diseases 0.000 claims description 6
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 6
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims description 6
- 208000030159 metabolic disease Diseases 0.000 claims description 6
- 201000006417 multiple sclerosis Diseases 0.000 claims description 6
- 230000035772 mutation Effects 0.000 claims description 6
- 230000036407 pain Effects 0.000 claims description 6
- 230000002085 persistent effect Effects 0.000 claims description 6
- 208000022821 personality disease Diseases 0.000 claims description 6
- 208000014081 polyp of colon Diseases 0.000 claims description 6
- 208000028173 post-traumatic stress disease Diseases 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 6
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 6
- 230000036280 sedation Effects 0.000 claims description 6
- 208000019116 sleep disease Diseases 0.000 claims description 6
- 125000002328 sterol group Chemical group 0.000 claims description 6
- 208000011117 substance-related disease Diseases 0.000 claims description 6
- 208000011580 syndromic disease Diseases 0.000 claims description 6
- 230000009529 traumatic brain injury Effects 0.000 claims description 6
- 208000029028 brain injury Diseases 0.000 claims description 3
- 206010009887 colitis Diseases 0.000 claims description 3
- 230000002996 emotional effect Effects 0.000 claims description 3
- 208000007386 hepatic encephalopathy Diseases 0.000 claims description 3
- 230000000394 mitotic effect Effects 0.000 claims description 3
- 208000009999 tuberous sclerosis Diseases 0.000 claims description 3
- OZUCXGWYZVDFOU-UHFFFAOYSA-N 2-(diethylamino)ethyl 6-hydroxy-4,7-dimethoxy-1-benzofuran-5-carboxylate;hydrochloride Chemical compound [Cl-].CC[NH+](CC)CCOC(=O)C1=C(O)C(OC)=C2OC=CC2=C1OC OZUCXGWYZVDFOU-UHFFFAOYSA-N 0.000 claims description 2
- JCSGAUKCDAVARS-SOUFLCLCSA-N chembl2106517 Chemical compound C1([C@@H](O)[C@H]2C3)=CC=CC(O)=C1C(=O)C2=C(O)[C@@]1(O)[C@@H]3[C@H](N(C)C)C(O)=C(C(N)=O)C1=O JCSGAUKCDAVARS-SOUFLCLCSA-N 0.000 claims description 2
- -1 -OR C Chemical group 0.000 claims 4
- 206010002153 Anal fissure Diseases 0.000 claims 1
- 206010011878 Deafness Diseases 0.000 claims 1
- 208000009531 Fissure in Ano Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 230000001771 impaired effect Effects 0.000 claims 1
- 231100000886 tinnitus Toxicity 0.000 claims 1
- 0 CC(C[C@@](C)[C@@](CC1)C2(C)[C@@]1C1C(C)(*)C=C(C[C@](*)(CC3)O)[C@@]3(C)[C@]1CC2)C(C)C(C(*)(*)O)=C Chemical compound CC(C[C@@](C)[C@@](CC1)C2(C)[C@@]1C1C(C)(*)C=C(C[C@](*)(CC3)O)[C@@]3(C)[C@]1CC2)C(C)C(C(*)(*)O)=C 0.000 description 85
- 238000000034 method Methods 0.000 description 63
- 208000034693 Laceration Diseases 0.000 description 5
- 208000016354 hearing loss disease Diseases 0.000 description 5
- 206010047571 Visual impairment Diseases 0.000 description 4
- 208000029257 vision disease Diseases 0.000 description 4
- 230000004393 visual impairment Effects 0.000 description 4
- 208000014644 Brain disease Diseases 0.000 description 3
- 208000018152 Cerebral disease Diseases 0.000 description 3
- 208000032274 Encephalopathy Diseases 0.000 description 3
- 230000008993 bowel inflammation Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000001314 paroxysmal effect Effects 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 230000001568 sexual effect Effects 0.000 description 3
- 201000007772 internal hemorrhoid Diseases 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022003714A JP2022036260A (ja) | 2016-09-30 | 2022-01-13 | Ｃ７置換オキシステロールおよびｎｍｄａモジュレーターとしての方法 |
| JP2024041201A JP7908981B2 (ja) | 2016-09-30 | 2024-03-15 | Ｃ７置換オキシステロールおよびｎｍｄａモジュレーターとしての方法 |
| JP2026074062A JP2026116412A (ja) | 2016-09-30 | 2026-04-27 | Ｃ７置換オキシステロールおよびｎｍｄａモジュレーターとしての方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662402789P | 2016-09-30 | 2016-09-30 | |
| US201662402797P | 2016-09-30 | 2016-09-30 | |
| US62/402,797 | 2016-09-30 | ||
| US62/402,789 | 2016-09-30 | ||
| PCT/US2017/054657 WO2018064649A1 (en) | 2016-09-30 | 2017-09-30 | C7 substituted oxysterols and methods as nmda modulators |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022003714A Division JP2022036260A (ja) | 2016-09-30 | 2022-01-13 | Ｃ７置換オキシステロールおよびｎｍｄａモジュレーターとしての方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019529495A JP2019529495A (ja) | 2019-10-17 |
| JP2019529495A5 true JP2019529495A5 (enExample) | 2020-11-12 |
| JP7149266B2 JP7149266B2 (ja) | 2022-10-06 |
Family
ID=60117790
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019517289A Active JP7149266B2 (ja) | 2016-09-30 | 2017-09-30 | Ｃ７置換オキシステロールおよびｎｍｄａモジュレーターとしての方法 |
| JP2022003714A Withdrawn JP2022036260A (ja) | 2016-09-30 | 2022-01-13 | Ｃ７置換オキシステロールおよびｎｍｄａモジュレーターとしての方法 |
| JP2026074062A Pending JP2026116412A (ja) | 2016-09-30 | 2026-04-27 | Ｃ７置換オキシステロールおよびｎｍｄａモジュレーターとしての方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022003714A Withdrawn JP2022036260A (ja) | 2016-09-30 | 2022-01-13 | Ｃ７置換オキシステロールおよびｎｍｄａモジュレーターとしての方法 |
| JP2026074062A Pending JP2026116412A (ja) | 2016-09-30 | 2026-04-27 | Ｃ７置換オキシステロールおよびｎｍｄａモジュレーターとしての方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US11149056B2 (enExample) |
| EP (1) | EP3519422B1 (enExample) |
| JP (3) | JP7149266B2 (enExample) |
| CN (3) | CN121085986A (enExample) |
| AU (1) | AU2017337121B2 (enExample) |
| CA (1) | CA3038900A1 (enExample) |
| ES (1) | ES2935057T3 (enExample) |
| MA (1) | MA46351A (enExample) |
| MX (1) | MX392270B (enExample) |
| PT (1) | PT3519422T (enExample) |
| WO (1) | WO2018064649A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE062616T2 (hu) | 2011-09-08 | 2023-11-28 | Sage Therapeutics Inc | Neuroaktív szteroidok, készítmények és alkalmazásaik |
| FI3932932T3 (fi) | 2013-03-13 | 2025-10-15 | Sage Therapeutics Inc | Neuroaktiivisia steroideja ja niiden käyttömenetelmiä |
| JP6628745B2 (ja) | 2014-06-18 | 2020-01-15 | セージ セラピューティクス， インコーポレイテッド | オキシステロールおよびその使用方法 |
| PT3319611T (pt) | 2015-07-06 | 2021-04-22 | Sage Therapeutics Inc | Oxisteróis e métodos de utilização dos mesmos |
| DK3812392T3 (da) | 2015-07-06 | 2025-07-21 | Sage Therapeutics Inc | Oxysteroler og fremgangsmåder til anvendelse deraf |
| ES2921010T3 (es) | 2016-04-01 | 2022-08-16 | Sage Therapeutics Inc | Oxisteroles y procedimientos de uso de los mismos |
| WO2017193046A1 (en) | 2016-05-06 | 2017-11-09 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| WO2018009867A1 (en) | 2016-07-07 | 2018-01-11 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| MA46351A (fr) * | 2016-09-30 | 2021-06-02 | Sage Therapeutics Inc | Oxystérols substitués en c7 et procédés en tant que modulateurs nmda |
| KR102521573B1 (ko) | 2016-10-18 | 2023-04-14 | 세이지 테라퓨틱스, 인크. | 옥시스테롤 및 그의 사용 방법 |
| DK3529257T3 (da) | 2016-10-18 | 2023-08-07 | Sage Therapeutics Inc | Oxysteroler og fremgangsmåder til anvendelse deraf |
| US10857163B1 (en) | 2019-09-30 | 2020-12-08 | Athenen Therapeutics, Inc. | Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof |
| WO2022235820A1 (en) * | 2021-05-04 | 2022-11-10 | Sage Therapeutics, Inc. | Neuroactive steroid for the treatment of mild cognitive impairment associated with parkinson's disease |
| EP4351588A1 (en) * | 2021-06-11 | 2024-04-17 | Sage Therapeutics, Inc. | Neuroactive steroid for the treatment of alzheimer's disease |
| EP4405370A1 (en) * | 2021-09-22 | 2024-07-31 | Sage Therapeutics, Inc. | Deuterated positive nmda-modulating compounds and methods of use thereof |
| IT202400014941A1 (it) * | 2024-06-28 | 2025-12-28 | Ind Chimica Srl | Processo per la preparazione di (4s)-4-(4-ciano-2-metossifenil)-5-etossi-1,4-diidro-2,8-dimetil-1,6-naftiridina-3-carbossammide |
Family Cites Families (119)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2259698A (en) | 1938-05-07 | 1941-10-21 | Rare Chemicals Inc | Physiologically effective substance and process of preparing same |
| US2594323A (en) | 1948-07-22 | 1952-04-29 | Upjohn Co | 24-substituted delta 5-cholene-3, 24-diols |
| US2673206A (en) | 1950-06-07 | 1954-03-23 | Schering Corp | 25-ethinyl steroids |
| US3079385A (en) | 1961-01-24 | 1963-02-26 | Roussel Uclaf | Novel process of preparation of polyhydroxylated pregnanes |
| US3206459A (en) | 1962-10-19 | 1965-09-14 | Syntex Corp | 10alpha-pregnan-19-ol derivatives |
| JPS5324071B2 (enExample) | 1974-04-30 | 1978-07-18 | ||
| US4071625A (en) | 1974-05-13 | 1978-01-31 | Richardson-Merrell Inc. | 19-Oxygenated-5α-androstanes for the enhancement of libido |
| CH628907A5 (en) | 1975-10-10 | 1982-03-31 | Hoffmann La Roche | Process for the preparation of 24,25-dihydroxycholesterol derivatives |
| JPS5840960B2 (ja) | 1976-12-28 | 1983-09-08 | 帝人株式会社 | ヒドロキシコレステロ−ル立体異性体間の相互変換法 |
| US4183852A (en) | 1977-07-18 | 1980-01-15 | Kaiser Emil T | Process for preparing 25-hydroxycholesterol |
| JPS54163565A (en) | 1978-06-09 | 1979-12-26 | Teijin Ltd | 24*255epoxyy3beta * 266 dihydroxyychlestoo55ene or protected derivative of hydroxyl group thereof and production |
| US4174345A (en) | 1978-08-01 | 1979-11-13 | Kaiser Emil T | Synthesis of steroids |
| US4269777A (en) | 1979-05-21 | 1981-05-26 | Wisconsin Alumni Research Foundation | Isotopically labeled vitamin D derivatives and processes for preparing same |
| JPS5735597A (en) | 1980-08-13 | 1982-02-26 | Teijin Ltd | 25,26-epoxy-3beta,24-dihydroxycholest-5-ene or its hydroxyl- protected derivative and their preparation |
| US4358406A (en) | 1981-07-27 | 1982-11-09 | Wisconsin Alumni Research Foundation | 26,26,26,27,27,27-Hexafluoro-1α,25-dihydroxycholecalciferol and process for preparing same |
| JPS61254599A (ja) | 1985-05-07 | 1986-11-12 | Sumitomo Pharmaceut Co Ltd | コレステロ−ルのフツ素誘導体 |
| JPS6253960A (ja) | 1985-05-30 | 1987-03-09 | Taisho Pharmaceut Co Ltd | ビタミンｄ↓３の誘導体 |
| JPS62187485A (ja) | 1986-02-13 | 1987-08-15 | Teijin Ltd | ２４，２５−エポキシコレステロ−ル類の製造法 |
| EP0382790A4 (en) | 1987-08-25 | 1991-03-27 | Kelvin W. Gee | Compositions and methods for alleviating stress, anxiety and seizure activity |
| US5232917A (en) | 1987-08-25 | 1993-08-03 | University Of Southern California | Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| JP4008024B2 (ja) | 1993-05-24 | 2007-11-14 | パーデュー、ファーマ、リミテッド、パートナーシップ | Ｇａｂａａレセプター複合体と相互作用させるための化合物 |
| IL110309A0 (en) | 1993-07-15 | 1994-10-21 | Univ Kentucky Res Found | A method of protecting against neuron loss |
| DE4338316A1 (de) | 1993-11-10 | 1995-05-11 | Jenapharm Gmbh | Neue Steroide mit radikophilen Substituenten, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel |
| DK1038880T3 (da) | 1994-02-14 | 2008-03-03 | Euro Celtique Sa | Androstaner og pregnaner til allosterisk modulering af GABA-receptor |
| IL112778A0 (en) | 1994-03-04 | 1995-05-26 | Merck & Co Inc | Substituted heterocycles, their preparation and pharmaceutical compositions containing them |
| US5595996A (en) * | 1994-10-25 | 1997-01-21 | Merck & Co., Inc. | 7-substituted 4-aza cholanic acid derivatives and their use |
| BR9509764A (pt) | 1994-11-23 | 1998-07-07 | Cocensys Inc | Série androstano e pregnano para modulação alostérica de receptor de gaba |
| JPH08268917A (ja) | 1995-03-31 | 1996-10-15 | D D S Kenkyusho:Kk | 癌組織への移行性の高い制癌剤 |
| PT837874E (pt) | 1995-06-06 | 2005-03-31 | Euro Celtique Sa | Esteroides neuroactivos da serie androstano e pregnano |
| US5792635A (en) | 1995-06-07 | 1998-08-11 | Magainin Pharmaceuticals, Inc. | Method of inhibiting the sodium/proton exchanger NHE3 and method of inhibiting growth by administering squalamine |
| US6645953B2 (en) | 1995-06-23 | 2003-11-11 | Novo Nordisk A/S | Meiosis regulating compounds |
| ATE254628T1 (de) | 1995-06-23 | 2003-12-15 | Novo Nordisk As | Meiose regulierende verbindungen. |
| JP4313435B2 (ja) | 1995-07-24 | 2009-08-12 | トラスティーズ オブ ボストン ユニバーシティー | プレグネノロンサルフェート誘導体によるｎｍｄａレセプター活性の抑制 |
| US5888996A (en) | 1995-07-26 | 1999-03-30 | Trustees Of Boston University | Inhibition of NMDA receptor activity and modulation of glutamate-mediated synaptic activity |
| WO1997042215A1 (en) | 1996-05-06 | 1997-11-13 | Bionumerik Pharmaceuticals, Inc. | Process for preparing 27-hydroxy cholesterol and related derivatives |
| JPH09328498A (ja) | 1996-06-10 | 1997-12-22 | Teijin Ltd | ２４，２５−ジヒドロキシコレステロールの製造法およびその合成中間体 |
| AU3967297A (en) | 1996-08-01 | 1998-02-25 | Cocensys, Inc. | Use of gaba and nmda receptor ligands for the treatment of migraine headache |
| DE19635525A1 (de) | 1996-08-20 | 1998-02-26 | Schering Ag | 7alpha-(xi-Aminoalkyl)-estratriene, Verfahren zu deren Herstellung, pharmazeutische Präparate, die diese 7alpha(xi-Aminoalkyl-estratriene enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln |
| US6122371A (en) | 1997-07-22 | 2000-09-19 | Atwell; Ronald C. | Apparatus for protecting coin-operated telephones from vandalism and larceny |
| CA2331299A1 (en) | 1998-05-11 | 1999-11-18 | Novo Nordisk A/S | Substituted guanidines and diaminonitroethenes, their preparation and use |
| KR20010043558A (ko) | 1998-05-13 | 2001-05-25 | 한센 핀 베네드, 안네 제헤르, 웨이콥 마리안느 | 감수분열 조절 화합물 |
| US8541600B2 (en) | 1998-11-24 | 2013-09-24 | Harbor Therapeutics, Inc. | 11-aza, 11-thia and 11-oxa sterol compounds and compositions |
| DE19917930A1 (de) | 1999-04-15 | 2000-10-19 | Schering Ag | Ent-Steroide als selektiv wirksame Estrogene |
| UA73736C2 (en) | 1999-04-29 | 2005-09-15 | Euro Celtic S A | Method for alleviating or preventing insomnia and inducing anesthesia |
| GB9910934D0 (en) | 1999-05-11 | 1999-07-14 | Res Inst Medicine Chem | Chemical compounds |
| CN1111167C (zh) | 1999-10-22 | 2003-06-11 | 中国科学院上海有机化学研究所 | 3β－羟基－5－胆烯酸酯类衍生物、合成方法及其用途 |
| CN1098273C (zh) * | 1999-11-12 | 2003-01-08 | 中国科学院上海有机化学研究所 | 高立体选择性的合成24r,25－和24s,25－二羟基甾体化合物 |
| GB0000228D0 (en) | 2000-01-06 | 2000-03-01 | Phytopharm Plc | Fluoro substituted sapogenins and their use |
| GB0019290D0 (en) | 2000-08-04 | 2000-09-27 | Symphar Sa | Methods for inducing apolipoprotein E secretion |
| GR1003861B (el) | 2000-12-29 | 2002-04-11 | Νεα νευροστεροειδη που αλληλεπιδρουν με τον υποδοχεα gabaa. | |
| GB0107822D0 (en) | 2001-03-28 | 2001-05-23 | Phytopharm Plc | Sapogenin derivatives their synthesis and use methods based upon their use |
| US20070197484A1 (en) | 2001-05-03 | 2007-08-23 | Ching Song | Method of treating disorder related to high cholesterol concentration |
| JP4309661B2 (ja) | 2001-05-03 | 2009-08-05 | ザ ユニバーシティー オブ シカゴ | 肝臓ｘ受容体 |
| WO2003039480A2 (en) | 2001-11-08 | 2003-05-15 | The University Of Chicago | Method of treating disorder related to high cholesterol concentration |
| AU2002360489A1 (en) | 2001-12-07 | 2003-06-23 | The Regents Of The University Of California | Treatment for age-related macular degeneration |
| PL213697B1 (pl) | 2002-03-27 | 2013-04-30 | Phytopharm Plc | Substancje czynne do stosowania w leczeniu chorób, zwlaszcza chorób neurodegeneracyjnych |
| KR101130212B1 (ko) | 2002-03-27 | 2012-04-13 | 파이토팜 피엘씨 | 사포게닌 및 그 유도체의 치료 방법 및 사용법 |
| US6933312B2 (en) | 2002-10-07 | 2005-08-23 | Agouron Pharmaceuticals, Inc. | Pyrazole derivatives |
| AU2003288231A1 (en) | 2002-12-13 | 2004-07-09 | Bayer Healthcare Ag | Cholesterol 24-hydroxylase (cyp46) as therapeutic target for the treatment of alzheimer's disease |
| FR2850023B1 (fr) | 2003-01-17 | 2007-04-06 | Mapreg | Medicaments pour le systeme nerveux |
| GB0403889D0 (en) | 2004-02-21 | 2004-03-24 | Univ Edinburgh | Uses of er-beta modulators |
| WO2006037016A2 (en) | 2004-09-27 | 2006-04-06 | The Regents Of The University Of California | Novel therapy for treatment of chronic degenerative brain diseases and nervous system injury |
| US20070032464A1 (en) | 2004-10-08 | 2007-02-08 | Shutsung Liao | Methods of treating cancers |
| EP1814558B1 (en) | 2004-11-01 | 2010-12-15 | Seo Hong Yoo | Methods and compositions for reducing neurodegeneration in amyotrophic lateral sclerosis |
| AU2007217366A1 (en) | 2006-02-27 | 2007-08-30 | The Regents Of The University Of California | Oxysterol compounds and the hedgehog pathway |
| CN101164540A (zh) | 2006-08-03 | 2008-04-23 | 中山大学 | 海洋甾体化合物在制备治疗神经元损伤药物中的应用 |
| GB0619860D0 (en) | 2006-10-06 | 2006-11-15 | Birkeland Innovasjon As | Treatment of insulin resistance and disorders associated therewith |
| US8273747B2 (en) | 2006-11-02 | 2012-09-25 | Curis, Inc. | Small organic molecule regulators of cell proliferation |
| JP2008268917A (ja) | 2007-03-26 | 2008-11-06 | Kyocera Mita Corp | 液体現像剤循環装置および画像形成装置 |
| AU2008265595B2 (en) | 2007-06-20 | 2014-12-04 | PureTech LYT 100 Inc. | Substituted N-Aryl pyridinones as fibrotic inhibitors |
| GB0712494D0 (en) | 2007-06-27 | 2007-08-08 | Isis Innovation | Substrate reduction therapy |
| US20110118353A1 (en) | 2007-11-06 | 2011-05-19 | N. V. Organon | Method of hormone suppression in humans |
| US9526737B2 (en) | 2007-12-03 | 2016-12-27 | The Regents Of The University Of California | Oxysterols for activation of hedgehog signaling, osteoinduction, antiadipogenesis, and Wnt signaling |
| WO2009090063A1 (en) | 2008-01-16 | 2009-07-23 | Jado Technologies Gmbh | Steroid sapogenin, androstane and triterpenoid sapogenin derivatives for the treatment and prevention of infectious diseases |
| WO2009094279A1 (en) | 2008-01-25 | 2009-07-30 | Merck & Co., Inc. | Quinolizidinone m1 receptor positive allosteric modulators |
| WO2009137843A2 (en) | 2008-05-09 | 2009-11-12 | Emory University | Nmda receptor antagonists for the treatment of neuropsychiatric disorders |
| WO2010065709A2 (en) | 2008-12-03 | 2010-06-10 | Amin Khan | Hydroxamic acid derivatives, preparation and therapeutic uses thereof |
| US20120040916A1 (en) | 2008-12-22 | 2012-02-16 | Massachusetts Institute Of Technology | Molecular inhibitors of the wnt/beta-catenin pathway |
| US20110319416A1 (en) | 2009-01-28 | 2011-12-29 | Emory University | Subunit Selective NMDA Receptor Antagonists For The Treatment Of Neurological Conditions |
| JP2013500986A (ja) | 2009-07-29 | 2013-01-10 | ザ・ユニバーシティ・オブ・シカゴ | 肝臓ｘ受容体アゴニスト |
| WO2011028794A2 (en) | 2009-09-01 | 2011-03-10 | Lazarus Therapeutics, Inc. | Treatment of huntington's disease with cycloserine and an nmda receptor antagonist |
| FR2953138B1 (fr) | 2009-12-02 | 2015-10-16 | Assist Publ Hopitaux Marseille | Composes aminosteroidiens pour une application topique locale pour la decolonisation cutaneo-muqueuse de staphylococcus aureus |
| WO2011092127A1 (en) | 2010-01-26 | 2011-08-04 | Bayer Schering Pharma Aktiengesellschaft | 14,17-bridged estratriene derivatives comprising heterocyclic bioisosteres for the phenolic a-ring |
| KR101692275B1 (ko) | 2010-02-11 | 2017-01-04 | 노오쓰웨스턴 유니버시티 | ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도 |
| US8247436B2 (en) | 2010-03-19 | 2012-08-21 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of CF |
| US20120035156A1 (en) | 2010-08-09 | 2012-02-09 | Daniela Alberati | Combination of glyt1 compound with antipsychotics |
| US8969525B2 (en) | 2010-11-09 | 2015-03-03 | Enzo Life Sciences, Inc. | Hydroxycholesterol immunoassay |
| WO2012142039A1 (en) | 2011-04-15 | 2012-10-18 | University Of North Dakota | Combination of liver x receptor modulator and estrogen receptor modulator for the treatment of age-related diseases |
| AU2012262520A1 (en) | 2011-05-27 | 2014-01-23 | Cytocure Llc | Methods, compositions, and kits for the treatment of cancer |
| WO2013019711A2 (en) | 2011-07-29 | 2013-02-07 | The Regents Of The University Of California | NOVEL 17β-HETEROARYL-SUBSTITUTED STEROIDS AS MODULATORS OF GABAA RECEPTORS |
| HUE062616T2 (hu) | 2011-09-08 | 2023-11-28 | Sage Therapeutics Inc | Neuroaktív szteroidok, készítmények és alkalmazásaik |
| US8648079B2 (en) | 2011-10-07 | 2014-02-11 | Takeda Pharmaceutical Company Limited | Heterocyclic compounds |
| EP4717314A2 (en) | 2011-10-14 | 2026-04-01 | Sage Therapeutics, LLC | 3,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof |
| US20150119327A1 (en) | 2012-04-25 | 2015-04-30 | The Regents Of The University Of California | Drug screening platform for rett syndrome |
| US20140149272A1 (en) | 2012-08-17 | 2014-05-29 | Trueex Group Llc | Interoffice bank offered rate financial product and implementation |
| DK2935307T3 (en) | 2012-12-18 | 2018-07-30 | Univ Washington | NEUROACTIVE 19-ALKOXY-17-SUBSTITUTED STEROIDS USED IN METHODS OF TREATMENT |
| WO2014115167A2 (en) | 2013-01-23 | 2014-07-31 | Sphaera Pharma Pvt. Ltd. | Novel compounds of 11beta-hydroxy-steroids for use in mitochondria biogenesis and diseases associated with mitochondrial dysfunction or depletion |
| JP6419087B2 (ja) | 2013-01-29 | 2018-11-07 | アプティニックス インコーポレイテッド | スピロラクタム系ｎｍｄａ受容体モジュレーターおよびその使用 |
| CN112057457A (zh) | 2013-03-13 | 2020-12-11 | 萨奇治疗股份有限公司 | 神经活性类固醇、组合物、及其用途 |
| FI3932932T3 (fi) | 2013-03-13 | 2025-10-15 | Sage Therapeutics Inc | Neuroaktiivisia steroideja ja niiden käyttömenetelmiä |
| HK1222565A1 (zh) | 2013-09-25 | 2017-07-07 | 范安德尔研究所 | 高效糖皮質激素 |
| JP6628745B2 (ja) | 2014-06-18 | 2020-01-15 | セージ セラピューティクス， インコーポレイテッド | オキシステロールおよびその使用方法 |
| EP3166613A4 (en) | 2014-07-09 | 2018-02-21 | Duke University | Compositions and methods for the repair of myelin |
| BR112017007053A2 (pt) | 2014-10-07 | 2018-06-19 | Sage Therapeutics Inc | compostos neuroativos e métodos de utilização deste composto. |
| DK3812392T3 (da) | 2015-07-06 | 2025-07-21 | Sage Therapeutics Inc | Oxysteroler og fremgangsmåder til anvendelse deraf |
| WO2017007832A1 (en) | 2015-07-06 | 2017-01-12 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| PT3319611T (pt) | 2015-07-06 | 2021-04-22 | Sage Therapeutics Inc | Oxisteróis e métodos de utilização dos mesmos |
| GB2557875A (en) | 2015-09-02 | 2018-07-04 | Univ Swansea | Diagnostic methods and kits |
| ES2921010T3 (es) | 2016-04-01 | 2022-08-16 | Sage Therapeutics Inc | Oxisteroles y procedimientos de uso de los mismos |
| WO2017193046A1 (en) | 2016-05-06 | 2017-11-09 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| WO2018009867A1 (en) | 2016-07-07 | 2018-01-11 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| CA3030420C (en) | 2016-07-11 | 2025-11-18 | Sage Therapeutics, Inc. | C7, C12 AND C16 SUBSTITUTED NEUROACTIVE STEROIDS AND ASSOCIATED METHODS OF USE |
| MA46351A (fr) | 2016-09-30 | 2021-06-02 | Sage Therapeutics Inc | Oxystérols substitués en c7 et procédés en tant que modulateurs nmda |
| DK3529257T3 (da) * | 2016-10-18 | 2023-08-07 | Sage Therapeutics Inc | Oxysteroler og fremgangsmåder til anvendelse deraf |
| KR102521573B1 (ko) | 2016-10-18 | 2023-04-14 | 세이지 테라퓨틱스, 인크. | 옥시스테롤 및 그의 사용 방법 |
| JP7332478B2 (ja) | 2017-03-15 | 2023-08-23 | モデルナティエックス インコーポレイテッド | 脂質ナノ粒子製剤 |
| IL271343B2 (en) | 2017-06-23 | 2023-12-01 | Intercept Pharmaceuticals Inc | Methods and intermediates for the preparation of bile acid derivatives |
| SG11202004329TA (en) | 2017-11-10 | 2020-06-29 | Marinus Pharmaceuticals Inc | Ganaxolone for use in treating genetic epileptic disoders |
-
2017
- 2017-09-30 MA MA046351A patent/MA46351A/fr unknown
- 2017-09-30 AU AU2017337121A patent/AU2017337121B2/en active Active
- 2017-09-30 PT PT177847704T patent/PT3519422T/pt unknown
- 2017-09-30 MX MX2019003724A patent/MX392270B/es unknown
- 2017-09-30 CN CN202511041222.2A patent/CN121085986A/zh active Pending
- 2017-09-30 US US16/338,315 patent/US11149056B2/en active Active
- 2017-09-30 CA CA3038900A patent/CA3038900A1/en active Pending
- 2017-09-30 EP EP17784770.4A patent/EP3519422B1/en active Active
- 2017-09-30 CN CN201780072617.6A patent/CN110023323A/zh active Pending
- 2017-09-30 ES ES17784770T patent/ES2935057T3/es active Active
- 2017-09-30 JP JP2019517289A patent/JP7149266B2/ja active Active
- 2017-09-30 CN CN202211226669.3A patent/CN115850361B/zh active Active
- 2017-09-30 WO PCT/US2017/054657 patent/WO2018064649A1/en not_active Ceased
-
2021
- 2021-09-15 US US17/476,153 patent/US11926646B2/en active Active
-
2022
- 2022-01-13 JP JP2022003714A patent/JP2022036260A/ja not_active Withdrawn
-
2024
- 2024-02-01 US US18/430,056 patent/US12331070B2/en active Active
-
2025
- 2025-05-13 US US19/206,490 patent/US20250388622A1/en active Pending
-
2026
- 2026-04-27 JP JP2026074062A patent/JP2026116412A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019532078A5 (enExample) | ||
| JP2018519328A5 (enExample) | ||
| JP2018519351A5 (enExample) | ||
| JP2019532079A5 (enExample) | ||
| RU2021100620A (ru) | Оксистеролы и способы их применения | |
| HRP20211282T1 (hr) | Oksisteroli i postupci njihovog korištenja | |
| ATE531711T1 (de) | Für die behandlung von autoimmunerkrankungen und entzündlichen erkrankungen geeignete tetrahydrocyclopentaäbüindol-3- ylcarbonsäurederivate | |
| JP2017518323A5 (enExample) | ||
| EP3870565A1 (en) | Compounds and compositions for treating conditions associated with nlrp activity | |
| EA201170251A1 (ru) | ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ 1,2,3,4-ТЕТРАГИДРОЦИКЛОПЕНТА[b]ИНДОЛ-3-ИЛ)УКСУСНОЙ КИСЛОТЫ, ПРИМЕНИМЫЕ В ЛЕЧЕНИИ АУТОИММУННЫХ И ВОСПАЛИТЕЛЬНЫХ РАССТРОЙСТВ | |
| RU2019115113A (ru) | Оксистеролы и способы их применения | |
| US12134611B2 (en) | Compounds and compositions for treating conditions associated with NLRP activity | |
| JP2012522847A5 (enExample) | ||
| JP2019519587A5 (enExample) | ||
| MA50391B1 (fr) | Composés d' imidazo[4,5-b]pyridine et compositions pharmaceutiques les contenant destinés à traiter les troubles inflammatoires | |
| JP2018528985A5 (enExample) | ||
| CN103114231B (zh) | 一种Mg-Sn-Al变形镁合金及其制备方法 | |
| JP2019510051A5 (enExample) | ||
| BR112016023382B1 (pt) | Composto, medicamento, e, uso de um composto | |
| CY1117830T1 (el) | Υποκατεστημενα παραγωγα τρικυκλικων οξεων ως αγωνιστες του υποδοχεα s1p1 χρησιμα στην αγωγη αυτοανοσων και φλεγμονοδων διαταραχων | |
| JP2010523623A (ja) | Ｐ２ｘ７調節因子としてのピラゾール誘導体 | |
| JP2012111761A5 (enExample) | ||
| MA33533B1 (fr) | Compositions pharmaceutiques pour le traitement du cancer et d'autres maladies ou troubles | |
| CN101208301A (zh) | 作为p38激酶抑制剂的双环衍生物 | |
| JP2016514162A5 (enExample) |